Instrumento Inactivo

Otros idiomas PledPharma AB (publ) Nasdaq Stockholm

Acciones

SE0003815604

Tiempo real estimado Cboe Europe Otros sitios de cotización 17:25:00 20/05/2024			Varia. Cinco días.	Varia. 1 de enero.
7,1 ^SEK	-61,75 %		-0,74 %	+23,02 %

03/05	Egetis Therapeutics AB (publ) informa de los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
22/02	Egetis Therapeutics AB (publ) informa de los resultados del cuarto trimestre finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Bulletin from Egetis Therapeutics’ Annual General Meeting 2024	06/05
Egetis Therapeutics Q1 2024 - EU launch closing in	06/05
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	24/04
Egetis Therapeutics' : 2023 Annual Report published	15/04
Egetis Therapeutics’ 2023 Annual Report published	15/04
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	29/03
Egetis Therapeutics - Continued progress in Q4	23/02
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Egetis Therapeutics : – Corporate Presentation December 2023	27/12
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	22/12
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today	19/12
Egetis’ Investor Day on December 19: Agenda and Registration Details	14/12
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA	13/12
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA	13/12
Save the Date: Egetis to host Investor Day on December 19, 2023	01/12
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises	10/11
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan	10/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas PledPharma AB (publ) Nasdaq Stockholm

Acciones

SE0003815604

Otros idiomas

Filtros